Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Patient | Phase | Treatment | n | OS (mo) | PFS (mo) | RR | DCR |
Second-line treatment for advanced gastric cancer or GEJ adenocarcinoma (REGARD) | III | BSC | 117 | 3.8 | 1.3 | 2.6% | 23.1% |
Ramucirumab | 238 | 5.2 | 2.1 | 3.4% | 48.7% |
- Citation: Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755
- URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13741.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13741